This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva, Allergan Generics deal receives conditional EU clearance

( March 10, 2016, 13:50 GMT | Official Statement) -- MLex Summary: The European Commission has conditionally cleared plans by Teva Pharmaceutical Industries to acquire the generics business of Allergan. The EU watchdog was concerned that rivals wouldn’t be able to compete with the merged entity for some generic drugs because of distribution models and national market structures. The regulator cleared the transaction after the companies agreed to sell the “great majority” of Allergan Generics’ business in the UK and Ireland, and other assets.Full statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login